Physician profile
Vidhya Viswanathan
NPI 1588874069
$486.75
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2022: $15.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.18 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $124.16 | 2019 | |
| Medtronic Minimed, INC. | $47.98 | 2019 | |
| Insulet Corporation | $37.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.87 | 2019 | |
| Endo Pharmaceuticals INC. | $18.28 | 2019 | |
| Dexcom, INC. | $17.77 | 2019 | |
| Abbvie INC. | $15.70 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Viswanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.